Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Graziano

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
The Pharmacogenomics Journal|March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancerF Graziano, A Ruzzo, E Giacomini, et al.
Cancer Research|April 6, 2001
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markersF Guadagni, J Kantor, S Aloe, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
The Journal of Infectious Diseases|January 19, 2005
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in miceThomas C Greenough, Gregory J Babcock, Anjeanette Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 11, 2022
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active DosesZheng Yang, Surendran Rajendran, Vanessa Spires, et al.
The Pharmacogenomics Journal|June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyA Ruzzo, F Graziano, F Loupakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 12, 2018
Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read SequencingAmelia K Haj, Jaren M Arbanas, Aaron P Yamniuk, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
The Pharmacogenomics Journal|March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancerF Graziano, A Ruzzo, E Giacomini, et al.
Cancer Research|April 6, 2001
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markersF Guadagni, J Kantor, S Aloe, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
The Journal of Infectious Diseases|January 19, 2005
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in miceThomas C Greenough, Gregory J Babcock, Anjeanette Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 11, 2022
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active DosesZheng Yang, Surendran Rajendran, Vanessa Spires, et al.
The Pharmacogenomics Journal|June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyA Ruzzo, F Graziano, F Loupakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 12, 2018
Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read SequencingAmelia K Haj, Jaren M Arbanas, Aaron P Yamniuk, et al.
Pageof 17